Navigation Links
EntreMed Reports Clinical Program Progress and Company Update
Date:11/12/2008

ROCKVILLE, Md., Nov. 12, /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, reported corporate and clinical program updates for the third quarter 2008 and remaining fourth quarter 2008 objectives. The updates were given during a podium presentation by EntreMed President & CEO, James S. Burns, and web cast at the Rodman & Renshaw 10th Annual Healthcare Conference, being held this week in New York. An archive of Mr. Burns' live presentation is available on the Company's web site at http://www.entremed.com and can be accessed for 60 days.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

During the presentation, Mr. Burns reiterated the development status of the Company's pipeline of multi-mechanism drugs for the treatment of cancer and inflammatory diseases. Remarks during the presentation were focused on corporate objectives as they relate to the status of multiple oncology clinical trials currently underway, the Company's partnering goals, and financial position. Highlights of the presentation are listed below.

Corporate Highlights

-- EntreMed, Inc. reported third quarter royalty revenues of approximately

$3.5 million from sales of Thalomid(R). Royalty revenues for the full

year 2008 are expected to increase over 2007 based on additional sales

of Thalomid(R) resulting from Celgene's acquisition of Pharmion.

-- EntreMed, Inc. ended the third quarter 2008 with approximately $28

million in cash and short-term investments. The $28 million, together

with anticipated royalty inflows, is expected to fund planned operations

for more than 12 months.

-- Research and development expenses are expected to decline further in

2009 as the Company seeks partners for its ENMD-2076 kinase inhibitor

and rheumatoid arthritis programs and focuses down on its key clinical

programs. The Company is undergoing a review of its programs andexpects

to implement cost-saving measures in areas that are not essential to

meeting or accelerating its strategic clinical objectives for 2009.

These cost reductions, along with royalty revenues, are expected to

provide sufficient cash into 2010.

-- The Company is actively engaged in partnering discussions for its

Aurora/angiogenesis kinase inhibitor, ENMD-2076, and for Panzem(R) in

rheumatoid arthritis. EntreMed's goal is to select an appropriate

partner to accelerate the development for ENMD-2076 in the first half of

2009, and to partner Panzem(R) in RA by 2H09.

-- On October 3, 2008, the Company's stock was transferred from the

Nasdaq Global Market to the Nasdaq Capital Market. Trading of the

Company's stock was unaffected by the transfer. More recently, as a

result of Nasdaq's determination to temporarily suspend the minimum

$1.00 closing bid price rule based on the current extraordinary market

conditions, EntreMed received notification that it will have until July

6, 2009 to regain compliance with the minimum bid price rule.

Clinical Program Status

-- ENMD-2076 - Patients are currently being enrolled in the third cohort of

the Phase 1 clinical trial in advanced solid tumors. The

longest-treated patient on study has received six months of daily

dosing. Phase 1 results are anticipated in the first half of 2009. A

second Phase 1 study in patients with multiple myeloma is planned to

begin later this year. The Company is engaged in partnering discussions

for the ENMD-2076 program.

-- MKC-1 - The primary response rate endpoint has been met for the efficacy

portion of the MKC-1 Phase 1/2 study in combination with Alimta(R)

(pemetrexed) in patients with non-small cell lung cancer. EntreMed is

considering possible options for further studies in NSCLC patients which

could include continuation of the current single arm study or a

randomized Phase 2 study in the same patient population if additional

financial resources are available.

-- ENMD-1198 - The Phase 1 study in advanced cancer patients is nearing

completion. A dose-limiting toxicity has been reached. The Phase 1

program may be expanded to identify combination therapies and target

indications. The mechanism-of-action for ENMD-1198 indicates that

prostate cancer may be a key indication. Possible next steps for the

clinical development of ENMD-1198 are being considered in light of our

objectives for 2009.

-- Panzem(R) RA - The Company completed a healthy volunteer study and

results were submitted to the FDA. The study results reaffirmed the

safety of Panzem(R), even at higher doses than are anticipated for the

treatment of rheumatoid arthritis. Based on the FDA's review, the

Company now has a clear path forward for clinical development and will

consider its options relative to our objectives for 2009. Possible next

steps for the RA program could include a drug-drug interaction (DDI)

clinical trial with methotrexate and chronic animal toxicology studies,

followed by a Phase 2 study in RA patients. The Company is engaged in

partnering discussions for the Panzem(R) RA program.

Mr. Burns commented on the update, "Increased royalty revenues and strategic cost reductions should place the Company in a position to weather the current market conditions into 2010. Aggressive partnering efforts for our Aurora/angiogenesis inhibitor, ENMD-2076, are underway, which will help accelerate development of this exciting compound and provide the financial resources to maintain our clinical development plan. These are difficult market conditions but we will continue to be resilient in our strategies. While our stock price has suffered, we have continued to make excellent clinical progress. I am confident in our pipeline of multi-mechanism drugs for cancer and inflammatory diseases and I believe that we remain on course to achieve our clinical and partnering milestones."

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-2076, a selective angiogenic kinase inhibitor, and ENMD-1198, a novel antimitotic agent are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

CONTACT:

Ginny Dunn

Associate Director, Corporate

Communications & Investor Relations

EntreMed, Inc.

240.864.2643


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. EntreMed Receives Deloitte Technology Fast 50 Award
2. EntreMed to Present at the Bio 2007 Investor Forum
3. EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study
4. EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference
5. EntreMed Reports Third Quarter 2007 Financial Results
6. EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models
7. EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
8. EntreMed to Present at the Jesup & Lamont Emerging Growth Stock Conference
9. Dr. Ronald E. Cape to Retire from EntreMed Board of Directors
10. EntreMed Reports First Quarter 2008 Financial Results
11. EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... N.J. (PRWEB) , ... June 27, 2016 , ... Quality ... sources, yet in many ways they remain in the eye of the beholder, according ... (EBO), a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered ... Latin America . ... ... ... ...
(Date:6/23/2016)... Tenn. , June 23, 2016 /PRNewswire/ ... automating, integrating and transforming the patient payment ... of several innovative new products and services ... of its revenue cycle offerings. These award-winning ... more efficient workflows, remain compliant in an ...
Breaking Medicine Technology: